Redeye maintains its valuation of Orexo after the Q2 report, with a target of SEK 90 per share. As we expected, the company reported a loss of SEK 32.5m mainly due to higher operating costs and investments in digital therapy products and the stronger SEK. While there are some uncertainties around the stock, we believe the company has all it takes to succeed long-term.